Covered with room — book value rising. A monthly payer at $0.13 a share, $1.56 annualized, held unchanged through the second quarter — and second-quarter adjusted distributable earnings (ADE) of $0.60 a share covered the quarter’s $0.39 of dividends more than one and a half times over, up from $0.55 of ADE in the first quarter. Book value rose to $13.61 at June 30, 2026, up $0.05 on the quarter after dividends and up from $13.16 at December 31, 2025, for a 13.6% annualized economic return in the quarter. This is the mortgage-REIT shape done right: the dividend is paid out of spread and credit earnings with a cushion left over, and the book behind it is growing, not melting. The adapted checks below grade core earnings coverage, book-value trend, and leverage — there is no AFFO here, and none is pretended.
Key risk: Credit and funding — Ellington holds credit-sensitive loans and securitizations alongside Agency paper, and total debt-to-equity of 9.2× (mostly non-recourse securitization liabilities) means a credit or funding shock still reaches book value fast, even with recourse leverage of only 1.9×.
Changes if: Adjusted distributable earnings fall below the $0.39 quarterly dividend, book value falls for a second straight quarter, or recourse leverage rises materially past 1.9×. Any of those turns a covered payout into a cut question.
- ✓ADE coverage check: Second-quarter ADE of $0.60 a share covered the $0.39 dividend 1.54 times — the payout consumed only about 65% of distributable earnings, and ADE rose from $0.55 in the first quarter while the dividend stayed flat, so the cushion is widening, not narrowing.
- ✓Book-value check: Book value per share rose from $13.16 at December 31, 2025 to $13.56 at March 31, 2026 and $13.61 at June 30, 2026 — up after dividends in both quarters of 2026, the opposite of the book-value melt that condemns a mortgage REIT.
- !Leverage check: Recourse debt-to-equity of 1.9× at June 30 is modest for the sector, but total debt-to-equity of 9.2× including securitization liabilities is the real amplifier — the structure is only as calm as its funding markets, and 29% of recourse borrowings being long-term and non-mark-to-market is what keeps that leverage from biting first.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.